 "medicine, drug, drugs, tablets")
The Delhi High Court on Wednesday allowed Indian drug manufacturers Natco Pharma and Alembic Pharmaceuticals to export Sorafinat and Rivaroxiban, generics of German pharma major Bayer's own cancer and blood thinning medicines.
Bayer had initiated proceedings against the two Indian pharma companies to stop them from exporting the drug, which the defendants had claimed were being exported for purposes of experimentation and generation of valuable clinical trial data. Bayer had opposed this stance and argued that such exports did not meet the exceptions to patent infringement provided under Section 107A of the Indian Patents Act, 1970, as they violated conditions of
